CA
JAZZ icon

Capitolis Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Capitolis Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-14,205
Closed -$1.81M – 312
2021
Q4 		$1.81M Hold
14,205
– – 0.01% 421
2021
Q3 		$1.99M Buy
+14,205
New +$2.15M 0.02% 296

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return

Capitolis Advisors's JAZZ Position: Q1 2022 in Review

Capitolis Advisors sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2022, closing a stake of 14,205 shares — an estimated $1.81M sold.

Capitolis Advisors first reported a position in JAZZ in Q3 2021 and held it in 2 quarters. The position peaked at $1.99M in Q3 2021. 462 funds tracked by Wall St. Rank hold JAZZ as of Q1 2022.

  • Capitolis Advisors reported no remaining Jazz Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Capitolis Advisors sold 14,205 Jazz Pharmaceuticals shares in Q1 2022, an estimated $1.81M.
  • Capitolis Advisors first reported a position in Jazz Pharmaceuticals in Q3 2021 and held it in 2 quarters.
  • Capitolis Advisors's Jazz Pharmaceuticals position peaked at $1.99M in Q3 2021.
  • 462 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2022.

Based on Capitolis Advisors's 13F filing for Q1 2022, filed 12 May 2022.